Compare MMYT & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MMYT | NAMS |
|---|---|---|
| Founded | 2000 | 2019 |
| Country | India | Netherlands |
| Employees | N/A | 100 |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | 2010 | N/A |
| Metric | MMYT | NAMS |
|---|---|---|
| Price | $46.81 | $28.12 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $101.00 | $46.75 |
| AVG Volume (30 Days) | ★ 1.5M | 887.3K |
| Earning Date | 05-20-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.83 | $17.96 |
| Revenue Next Year | $17.24 | $540.65 |
| P/E Ratio | $107.67 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $32.67 | $16.79 |
| 52 Week High | $113.85 | $42.00 |
| Indicator | MMYT | NAMS |
|---|---|---|
| Relative Strength Index (RSI) | 53.30 | 35.47 |
| Support Level | $32.67 | $23.48 |
| Resistance Level | $51.39 | $37.25 |
| Average True Range (ATR) | 1.92 | 1.83 |
| MACD | 0.60 | -0.64 |
| Stochastic Oscillator | 60.00 | 3.94 |
MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.